{
    "nct_id": "NCT03477110",
    "official_title": "SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study",
    "inclusion_criteria": "* Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma\n* Karnofsky performance status (KPS) ≥ 60\n* Patients must have recovered from the effects of surgery per treating physician's judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment\n* Absolute neutrophil count (ANC) ≥ 1,000 cells/mm^3\n* Platelets ≥ 100,000 cells/mm^3\n* Hemoglobin ≥ 9.0 g/dl\n* Creatinine clearance > 30 mL/min\n* Bilirubin < 2.0 mg/dL\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range\n* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide\n* Is able to have magnetic resonance imaging (MRI) with contrast of the brain\n* All subjects must be able to comprehend and sign a written informed consent document. If the subject can comprehend the informed consent but is unable to sign, a LAR may sign the written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum or brainstem)\n* Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias\n* A skull defect (such as, missing bone with no replacement)\n* Women of childbearing potential who are pregnant or breastfeeding\n* Evidence of increased intracranial pressure (midline shift > 5 mm, clinically significant papilledema)\n* Serious medical or psychiatric illness likely to interfere with participation in this clinical study, in the opinion of the investigator\n* Prior radiation treatment to the brain\n* Prior treatment with temozolomide\n* Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\n* Known active collagen vascular disease",
    "miscellaneous_criteria": ""
}